The technological imperative and the battle for the hearts of America

Perspectives in Biology and Medicine

Volumn 50, Issue 2, 2007, Pages 276-294

  Gillick, Muriel R ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEVICE; ECONOMICS; FINANCIAL MANAGEMENT; HEALTH CARE; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HEART FAILURE; HUMAN; INDUSTRY; INVASIVE PROCEDURE; LEFT VENTRICULAR ASSIST DEVICE; POLITICS; PRIORITY JOURNAL; REVIEW; SCIENCE; TECHNOLOGY; WESTERN HEMISPHERE;

EID: 34248154692     PISSN: 00315982     EISSN: None     Source Type: Journal    
DOI: 10.1353/pbm.2007.0017     Document Type: Review

References (59)

1. Agovino, T. 2003. Expensive heart device expected to be rationed. Boston Globe, Sept. 2.
2. Angell, M. 2004. The truth about the drug companies: How they deceive us and what to do about it. New York: Random House.
3. Barker, W., J. Mullooly, and W. Getchell. 2006. Changing incidence and survival for heart failure in a well-defined older population, 1970-1974 and 1990-1994. Circulation 113: 799-805.
4. Boards of Trustees of the Federal Hospital Insurance and Federal Supplementary Medical Insurance Trust Funds. 2006. The 2006 annual report. Washington, DC: GPO.
5. Brown, D. 2006. Artificial heart gets limited FDA approval. Washington Post, Sept. 6.
6. Centers for Medicare and Medicaid Services (CMS). 2003. Medicare announces its intention to cover ventricular assist devices as destination therapy, Oct. 1. www.cms.hhs.gov/apps/media/press/release.asp?Counter=881.
7. Cohen, A. 2004a. The diffusion of new medical technology. In Technology in American health care, ed. A. Cohen and R. Hanftt, 79-104. Ann Arbor: Univ. of Michigan Press.
8. Cohen, A. 2004b. Biomedical innovation and the development of medical technology. In Technology in American health care, ed. A. Cohen and R. Hanftt, 45-78. Ann Arbor: Univ. of Michigan Press.
9. Columbia University Department of Surgery Newsletter. 2005. SCCOR grant supports extensive LVAD research. March. www.columbiasurgery.org/news/ research/2005_sccor_grant_lvad.html.
10. Committee on the NIH Research Priority-Setting Process, Health Science Policy Program Health, Sciences Section Institute of Medicine. 1998. Scientific opportunities and public needs: Improving priority setting and public input at the National Institute of Health. Washington, DC: National Academy Press.
11. DeBakey, M. 1971. Left ventricular bypass pump for left ventricular assistance. Am J Cardiol 27:3-11.
12. Delgado, R. 2006. The future. Paper presented at symposium "The cardiologist's new frontier: Mechanical support for heart failure," Texas Heart Institute, Houston, March 11.
13. Dudzinski, D. 2006. Ethics guidelines for destination therapy. Ann Thorac Surg 81:1185-88.
14. Feigal, D., S. Gardner, and M. McClellan. 2003. Ensuring safe and effective medical devices. N Engl J Med 341:191-92.
15. FischerHealth. 2006. How we helped Thoratec reach a new destination. www.fischer-health.com/case_mdd_tho.html.
16. Food and Drug Administration (FDA). 2006. CDER drugs and biological approvals for calendar year 2005. www.fda.gov/cder/rdmt/InternetNDA05.htm.
17. Foote, S. 2002. Why Medicare cannot promulgate a national coverage rule: A case of regula mortis. J Health Polit Policy Law 27(5):707-30.
18. Fox, R., and J. Swazey. 2004. "He knows that machine is his mortality": Old and new social and cultural patterns in the clinical trial of the AbioCor artificial heart. Perspect Biol Med 47(1):74-99.
19. Frazier, O., and R. Delgado. 2003. Mechanical circulatory support for advanced heart failure: Where does it stand in 2003? Circulation 108:3064-68.
20. Gelijns, A., and N. Rosenberg. 1994. The dynamics of technological change in medicine. Health Aff 23:28-46.
21. Gelijns, A., N. Rosenberg, and G. Laubach. 1996. Implantable and surgical medical devices. In Risk and innovation: Small companies in six industries, 33-60. Washington, DC: National Academy of Sciences.
22. Gillick, M. 2004. Medicare coverage for technological interventions: Time for new criteria? N Engl J Med 350:2199-2203.
23. Goldman, D., et al. 2005. Consequences of health trends and medical innovation for the future elderly. Health Aff 24:R5-R17.
24. Goldstein, N., and J. Lynn. 2006. Trajectory of end-stage heart failure: The influence of technology and implications for policy change. Perspect Biol Med 49(1):10-18.
25. Hadorn, D. 1991. Setting health care priorities in Oregon: Cost-effectiveness meets the rule of rescue. JAMA 265:2218-25.
26. Halasey, S. 2005. Affairs of the heart. Interview with Kenneth Grossman, CEO of Thoratec. MX business strategies for medical technology executives, Sept./Oct. http.//www.devicelink.com/mx/archive/05/09/contents. html.
27. Heart Failure Society of America. 2006. Comprehensive heart failure practice guideline. J Card Fail 12:e1-e122.
28. Hogness, J., and M. VanAntwerp, eds. 1991. The artificial heart: Prototypes, policies, and patients. Washington, DC: National Academies Press.
29. Hunt, S., et al. 2005. ACA/AHA guideline update for the diagnosis and management of chronic heart failure in the adult. Circulation 112:154-235.
30. Kirk, J. 2001. Machines in our hearts: The cardiac pacemaker, the implantable defibrillator, and American health care. Baltimore: Johns Hopkins Univ. Press.
31. Long, J., et al, 2005. Long-term "destination therapy" with the HeartMate XVE left ventricular assist device: Improved outcomes since the REMATCH study. Congest Heart Fail 11:155-56.
32. Lubitz, L. 2005. Health, technology, and medical care spending. Health Aff W5:R81-R85.
33. Maisel, W. 2005. Safety issues involving medical devices. JAMA 284:955-58.
34. McMurray, J., and S. Stewart. 2002. The burden of heart failure. Eur Heart J Supplements 4(suppl.):D50-D58.
35. Menzel, P., et al. 1999. Towards a broader view of values in cost-effectiveness analysis of health care. Hastings Cent Rep 29:7-15.
36. National Heart and Lung Institute (NHLI). 1973. A report of the artificial heart assessment panel. DHEW publ. no. (NIH) 74-191.
37. National Heart, Lung and Blood Institute (NHLBI) Working Group. 2004. Next generation ventricular assist device for destination therapy, Oct. 18. www.nhlbi.nih.gov/meetings/workshops/nextgen-vads.htm.
38. Office of Technology Assessment. U.S. Congress. 1976. Development of medical technology: Opportunities for assessment. Publ. no. OTA-H-34. Washington, DC: GPO.
39. Oz, M., et al. 2003. Left ventricular assist devices as permanent heart failure therapy: The price of progress. Ann Surg 238:577-85.
40. Phurrough, S., et al. 2003. National coverage analysis: Ventricular assist devices as destination therapy. www.cms.hhs.gov/ncdr/memo.asp?id=79.
41. Polsdorfer, R. 2005. Heart assist system implantation. Brigham and Women's Hospital Health Information, November. http://healthgate.partners.org/ browsing/browseContent.asp?filename=102863.xml&title=.
42. Radovancevic, B. 2006. Mechanical support for heart failure: Where we have been and where we are. Paper presented at symposium "The cardiologist's new frontier: Mechanical support for heart failure," Texas Heart Institute, March 11. http://texasheart.org/education/CME/explore/events/ eventdetail_5213.cfm.
43. Ramsey, S., et al. 1998. The limited state of technology assessment for medical devices: Facing the issues. Am J Man Care 4:SP188-SP199.
44. Rettig, R. 1994. Medical innovation duels cost containment. Health Aff 13:7-27.
45. Rinfret, S., et al. 2005. Cost-effectiveness of dual-chamber pacing compared with ventricular pacing for sinus node dysfunction. Circulation 11:165-71.
46. Rogers, E. 2003. Diffusion of innovations, 5th ed. New York: Free Press.
47. Rose, E., et al. 2001. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med 345:1435-43.
48. Rothman, D. 1997. Beginnings count. New York: Oxford Univ. Press.
49. Samson, D. 2004. Special report: Cost-effectiveness of left-ventricular assist devices as destination therapy for end-stage heart failure. TEC assessment program 19(2).
50. Savings, T. R. 2003. Statement before the Senate Special Committee on Aging. July 29.
51. SoRelle, R. 2004. Assisting the heart: A long and winding road. Findings at Baylor College of Medicine June. www.bcm.edu/findings/vol2/is6/04june_n1.htm.
52. Stevenson, L., and P. Shekar. 2005. Ventricular assist devices for durable support. Circulation 112:e111-e115.
53. Thoratec Corporation. 2003. Medicare expands coverage of left ventricular assist devices for destination therapy, Oct. 2. www.biobn.comindex.cfn?Page= viewnews/NewsID=0002028056.
54. Thoratec Corporation. 2004. Thoratec comments on the now effective increased Medicare reimbursement for destination therapy, Oct. 5. http://phx.corporate-ir.net/phoenix.zhtml?c=95989&p=irol-newsArticle&ID= 623730&highlight.
55. Thoratec Corporation. 2005a. How did the medical community respond to the Heart-Mate SNAP-LE LVAS for destination therapy? www.thoratec.com/heartmate- destination-therapy/heartmate_medical_quotes.htm.
56. Thoratec Corporation. 2005b. Thoratec says new heart failure guidelines show increasing acceptance of VADs as treatment option for heart failure patients, Sept. 1. http://phx.corporate-ir.net/phoenix.zhtml?c=95989&p=irol- newsArticle_Print&ID=751575&highlight.
57. Tunis, S. 2004. Why Medicare has not established criteria for coverage decisions. N Engl J Med 350:2196-98.
58. Weinstein, M., et al. 1996. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 276:1253-58.
59. Winkelmayer W., et al. 2002. Health economic evaluation: The special case of end-stage renal disease treatment. Med Decis Making 22:417-30.